Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Zura Bio Ltd (ZURA)

Zura Bio Ltd (ZURA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Business Wire - Thu May 14, 6:30AM CDT

Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with...

ZURA : 3.55 (-3.79%)
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer Business Wire - Wed May 13, 6:30AM CDT

Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and...

ZURA : 3.55 (-3.79%)
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates Business Wire - Thu May 7, 6:30AM CDT

Continuing advancement of two Phase 2 studies evaluating tibulizumab in hidradenitis suppurativa (HS) (TibuSHIELD) and systemic sclerosis (SSc) (TibuSURE), with both trials on track to meet anticipated...

ZURA : 3.55 (-3.79%)
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Business Wire - Mon May 4, 3:05PM CDT

Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with...

ZURA : 3.55 (-3.79%)
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates Business Wire - Thu Mar 19, 3:05PM CDT

Advancing two Phase 2 studies evaluating tibulizumab in hidradenitis suppurativa (HS) and systemic sclerosis (SSc) Topline data expected from the Phase...

ZURA : 3.55 (-3.79%)
Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress Business Wire - Thu Mar 5, 5:30AM CST

Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and...

ZURA : 3.55 (-3.79%)
Zura Bio to Participate in Upcoming Investor Conferences Business Wire - Mon Mar 2, 5:30AM CST

Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients...

ZURA : 3.55 (-3.79%)
Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares Business Wire - Fri Feb 27, 5:30AM CST

Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating...

ZURA : 3.55 (-3.79%)
Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants Business Wire - Wed Feb 25, 5:30AM CST

Zura Bio Limited (Nasdaq: ZURA), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune...

ZURA : 3.55 (-3.79%)
Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants Business Wire - Tue Feb 24, 3:01PM CST

Zura Bio Limited (Nasdaq: ZURA), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune...

ZURA : 3.55 (-3.79%)

Barchart Exclusives

AMD Stock Could Surge Past $665 on Explosive Data Center Demand Barchart - 8 minutes ago
Rising demand for CPUs and GPUs and expanding AI infrastructure spending position AMD to deliver solid growth. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.